<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03628807</url>
  </required_header>
  <id_info>
    <org_study_id>NEPTUN</org_study_id>
    <nct_id>NCT03628807</nct_id>
  </id_info>
  <brief_title>Non-invasive Evaluation Program for TIPS and Follow Up Network</brief_title>
  <acronym>NEPTUN</acronym>
  <official_title>Non-invasive Evaluation of Prognostic Parameters for Patients With Transjugular Intrahepatic Portosystemic Shunt (TIPS) Using a Structured Follow up Protocol</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Bonn</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Bonn</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluation of non-invasive prognostic parameters in patients receiving transjugular
      intrahepatic portosystemic shunt (TIPS) for complications of portal hypertension. Patients
      are cared according to the local standardized follow up program. Clinical and laboratory data
      from standard patient care are evaluated for potential prognostic value.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      NEPTUN consists of liver cirrhosis receiving transjugular intrahepatic portosystemic shunt
      (TIPS) at the Department of Internal Medicine I, University of Bonn, Germany and receiving a
      structured routine evaluation and follow up program. The diagnosis of cirrhosis was based on
      clinical, hemodynamic and biochemical parameters, and ultrasound and/or biopsy criteria.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 1999</start_date>
  <completion_date type="Actual">May 11, 2020</completion_date>
  <primary_completion_date type="Actual">May 11, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Survival</measure>
    <time_frame>up to 10 years</time_frame>
    <description>death, liver transplantation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ascites</measure>
    <time_frame>up to 10 years</time_frame>
    <description>Evaluation of amount of ascites according to the Child-Score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hepatic Encephalopathy</measure>
    <time_frame>up to 10 years</time_frame>
    <description>Evaluation of the grade according to the West Haven Criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Variceal Bleeding</measure>
    <time_frame>up to 10 years</time_frame>
    <description>Assessment of presence of variceal bleeding</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Liver Failure</measure>
    <time_frame>up to 10 years</time_frame>
    <description>defined as Bilirubin level â‰¥ 12mg/dl</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute-on-Chronic-Liver Failure (ACLF)</measure>
    <time_frame>up to 10 years</time_frame>
    <description>Presence of ACLF according to the EASL-Chronic liver Failure Consortium (CLIF)-criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Organ Failures</measure>
    <time_frame>up to 10 years</time_frame>
    <description>Assessment of Organ failures according to the CLIF-SOFA
according to CLIF-Sequential Organ Failure Assessment (SOFA) Score</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">747</enrollment>
  <condition>Portal Hypertension</condition>
  <arm_group>
    <arm_group_label>Retrospective 1</arm_group_label>
    <description>Retrospective Bare Metal Stent Cohort that received TIPS from 01/01/1996 to 12/31/2003.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Retrospective 2</arm_group_label>
    <description>Retrospective Covered Stent Cohort that received TIPS from 01/01/2004 to 12/31/2012.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prospective</arm_group_label>
    <description>Prospective cohort that received TIPS from 01/01/2013 onwards</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      serum, plasma, stool, DNA, PBMC, Buffi coat
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        All patients receiving TIPS according to guidelines
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Insertion of TIPS according to guidelines

        Exclusion Criteria:

          -  Contraindication for TIPS
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Praktiknjo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Bonn</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital Bonn</name>
      <address>
        <city>Bonn</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>July 11, 2018</study_first_submitted>
  <study_first_submitted_qc>August 9, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 14, 2018</study_first_posted>
  <last_update_submitted>May 11, 2020</last_update_submitted>
  <last_update_submitted_qc>May 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Bonn</investigator_affiliation>
    <investigator_full_name>Jonel Trebicka</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>transjugular intrahepatic portosystemic shunt (TIPS)</keyword>
  <keyword>non-invasive assessments</keyword>
  <keyword>Transthoracic echocardiography (TTE) with Speckle-tracking</keyword>
  <keyword>Computer tomography scan (CT-scan)</keyword>
  <keyword>Magnetic resonance imaging (MRI)</keyword>
  <keyword>circulating biomarkers</keyword>
  <keyword>Electroencephalography (EEG)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension, Portal</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

